The 2022 top 100 biopharma investors: A look back on boom times
RA Capital dominated the crossover game in 2021, running the table as a host of biotechs angled for a quick leap onto the public market …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
